NYSEAMERICAN:NSRX

Nasus Pharma (NSRX) Stock Price, News & Analysis

Nasus Pharma logo
$2.74 +0.13 (+4.98%)
As of 11:05 AM Eastern
This is a fair market value price provided by Massive. Learn more.

About Nasus Pharma Stock (NYSEAMERICAN:NSRX)

Advanced

Key Stats

Today's Range
$2.68
▼
$2.74
50-Day Range
$2.61
▼
$3.92
52-Week Range
$1.98
▼
$9.50
Volume
5,813 shs
Average Volume
72,431 shs
Market Capitalization
$32.09 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$12.50
Consensus Rating
Buy

Company Overview

Nasus Pharma is an Israel-based clinical-stage pharmaceutical company developing intranasal powder treatments intended for rapid use in emergency situations. Its platform is designed to deliver medicines through the nose without requiring an injection.

The company’s development programs focus on rescue treatments for conditions including opioid overdose and seizures. Nasus Pharma is working to advance these products through development and evaluation; they are not established marketed therapies.

AI Generated. May Contain Errors.

Nasus Pharma Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
70th Percentile Overall Score

NSRX MarketRank™: 
3.500466728895 of 5 stars

Nasus Pharma scored higher than 70% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Nasus Pharma has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on no strong buy ratings, 2 buy ratings, no hold ratings, and no sell ratings.

  • Upside Potential

    Nasus Pharma has a consensus price target of $12.50, representing about 378.9% upside from its current price of $2.61.

  • Amount of Analyst Coverage

    Nasus Pharma has only been the subject of 1 research reports in the past 90 days.

  • Read more about Nasus Pharma's stock forecast and price target.
  • Earnings Growth

    Earnings for Nasus Pharma are expected to grow in the coming year, from ($0.84) to ($0.81) per share.

  • Price to Book Value per Share Ratio

    Nasus Pharma has a P/B Ratio of 8.42. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

  • Percentage of Shares Shorted

    0.61% of the float of Nasus Pharma has been sold short.
  • Short Interest Ratio / Days to Cover

    Nasus Pharma has a short interest ratio ("days to cover") of 3.65, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Nasus Pharma has recently decreased by 11.72%, indicating that investor sentiment is improving significantly.
  • Dividend Yield

    Nasus Pharma does not currently pay a dividend.

  • Dividend Growth

    Nasus Pharma does not have a long track record of dividend growth.

  • News Sentiment

    Nasus Pharma has a news sentiment score of -0.01. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.56 average news sentiment score of Healthcare companies.
  • News Coverage This Week

    MarketBeat has tracked 4 news articles for Nasus Pharma this week, compared to 1 article on an average week.
  • MarketBeat Follows

    4 people have added Nasus Pharma to their MarketBeat watchlist in the last 30 days.
Receive NSRX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Nasus Pharma and its competitors with MarketBeat's FREE daily newsletter.

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

NSRX Stock News Headlines

Nasus Pharma appoints Nir Sassi as CFO
Your book is inside
The "Sucker's Bet" Most New Options Traders Fall For Most people who try options lose money the same way. They don't know the rules. They don't know what to avoid. And they hand their account to Wall Street on a silver platter. Normally $29.97. Free today.tc pixel
Nasus Pharma Appoints Nir Sassi as Chief Financial Officer
Nasus Pharma Appoints Nir Sassi as Chief Financial Officer
Nasus Pharma Ltd (NSRX)
See More Headlines

NSRX Stock Analysis - Frequently Asked Questions

Nasus Pharma's stock was trading at $7.10 at the start of the year. Since then, NSRX stock has decreased by 63.2% and is now trading at $2.61.

Shares of NSRX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Company Calendar

Last Earnings
8/17/2026
Today
11/18/2026
Fiscal Year End
12/31/2026

Industry, Sector and Symbol

Stock Exchange
NYSEAMERICAN
Industry
Pharmaceuticals
Sub-Industry
Pharmaceuticals
Current Symbol
NYSEAMERICAN:NSRX
CIK
2029039
Fax
N/A
Employees
7
Year Founded
N/A

Price Target and Rating

High Price Target
$18.00
Low Price Target
$7.00
Potential Upside/Downside
+356.2%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
2 Analysts

Profitability

EPS (Trailing Twelve Months)
N/A
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
N/A
Net Margins
N/A
Pretax Margin
N/A
Return on Equity
N/A
Return on Assets
N/A

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
8.77
Quick Ratio
N/A

Sales & Book Value

Annual Sales
N/A
Price / Sales
N/A
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$0.31 per share
Price / Book
8.84

Miscellaneous

Outstanding Shares
11,710,000
Free Float
N/A
Market Cap
$32.09 million
Optionable
N/A
Beta
4.25
The Infrastructure's Backbone: 10 Stocks Powering the AI Buildout Cover

The AI boom extends far beyond the biggest tech names. Discover 10 companies supplying the memory, storage, networking, semiconductor manufacturing, and power infrastructure that make AI possible. Learn where the next wave of AI investment opportunities may emerge—and the key risks investors should watch as the global AI buildout accelerates.

Get This Free Report

This page (NYSEAMERICAN:NSRX) was last updated on 11/18/2026 by MarketBeat.com Staff.
From Our Partners